Replies to post #671 on Acasti Pharma, Inc (ACST)

[CoolG73]

just a comparison to Vascepa, they reduced TG by 7% with the 2 g dose in the MARINE trial (severe HTG). Pierre the COO and CSO mentioned in his last interview that the Capre 2 g reduced the TG by 15% in the severe strata in the Trifecta trial. so if we were able to achieve double reduction with the 2 g , even with a small sample of patients, I don't see why we cant do better in the 4 g

[Glider549]

Even a jump to $5 would please me.
Two catalysts this month, be patient and cross your fingers folks.